Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CCCC
stocks logo

CCCC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
6.44M
-46.36%
--
--
6.84M
-55.47%
--
--
7.00M
+35.21%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for C4 Therapeutics, Inc. (CCCC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.78%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-4.78%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for C4 Therapeutics Inc (CCCC.O) is -0.97, compared to its 5-year average forward P/E of -6.38. For a more detailed relative valuation and DCF analysis to assess C4 Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.38
Current PE
-0.97
Overvalued PE
0.02
Undervalued PE
-12.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.91
Current EV/EBITDA
0.39
Overvalued EV/EBITDA
1.92
Undervalued EV/EBITDA
-11.74

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
30.03
Current PS
5.61
Overvalued PS
57.30
Undervalued PS
2.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CCCC News & Events

Events Timeline

(ET)
2025-11-06
07:20:40
C4 Therapeutics projects funding will last until the end of 2028.
select
2025-11-06
07:20:16
C4 Therapeutics Announces Q3 Earnings Per Share of 44 Cents, Exceeding Consensus Estimate of 38 Cents
select
2025-10-16 (ET)
2025-10-16
07:16:10
C4 Therapeutics sets price for $125M underwritten offering
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
12-03Benzinga
Coca-Cola Femsa Analyst Changes Stance; Discover Tuesday's Two Major Downgrades

  • Analyst Downgrades: Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV from Overweight to Equal-Weight, maintaining a price target of $98, while shares closed at $87.60.

  • 10x Genomics Rating Change: Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. from Overweight to Equal-Weight, raising the price target from $17 to $20, with shares closing at $18.08.

  • Market Overview: The article provides a snapshot of various stocks, including Coca-Cola Femsa and 10x Genomics, along with their recent performance and analyst ratings.

  • Investment Advice Disclaimer: The content is sourced from Benzinga, which does not provide investment advice and emphasizes the importance of consulting analysts for stock evaluations.

[object Object]
Preview
6.0
12-02Benzinga
Cloudflare Analyst Starts Coverage Optimistically; Check Out Tuesday's Top 5 Initiations

  • Analyst Ratings Initiations: Several Wall Street analysts have initiated coverage on various companies, providing new ratings and price targets for investors to consider.

  • Blackline Inc: Rosenblatt analyst Robert Simmons initiated coverage with a Buy rating and a price target of $65, while the stock closed at $56.09.

  • C4 Therapeutics Inc: TD Cowen analyst Tyler Van Buren also initiated coverage with a Buy rating, with shares closing at $2.54.

  • Cloudflare Inc and Others: Barclays analyst Saket Kalia gave Cloudflare an Overweight rating with a price target of $235, while UBS and Wells Fargo analysts provided ratings for Weatherford International and California Resources, respectively.

[object Object]
Preview
8.5
11-22SeekingAlpha
C4 Therapeutics Launches $400 Million Mixed Shelf Offering

  • Shelf Registration Filing: C4 Therapeutics has filed a shelf registration to offer up to $400 million in various securities, including common stock, preferred stock, debt securities, warrants, or units.

  • Recent Offerings and Presentations: The company recently priced a $125 million equity offering with warrants and has presented data on its Phase 1 trial of Cemsidomide in multiple myeloma at the IMS Annual Meeting 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is C4 Therapeutics Inc (CCCC) stock price today?

The current price of CCCC is 2.59 USD — it has decreased -7.83 % in the last trading day.

arrow icon

What is C4 Therapeutics Inc (CCCC)'s business?

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

arrow icon

What is the price predicton of CCCC Stock?

Wall Street analysts forecast CCCC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CCCC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is C4 Therapeutics Inc (CCCC)'s revenue for the last quarter?

C4 Therapeutics Inc revenue for the last quarter amounts to 7.24M USD, increased 138.17 % YoY.

arrow icon

What is C4 Therapeutics Inc (CCCC)'s earnings per share (EPS) for the last quarter?

C4 Therapeutics Inc. EPS for the last quarter amounts to -0.37 USD, decreased -9.76 % YoY.

arrow icon

What changes have occurred in the market's expectations for C4 Therapeutics Inc (CCCC)'s fundamentals?

The market is revising No Change the revenue expectations for C4 Therapeutics, Inc. (CCCC) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.78%.
arrow icon

How many employees does C4 Therapeutics Inc (CCCC). have?

C4 Therapeutics Inc (CCCC) has 110 emplpoyees as of December 05 2025.

arrow icon

What is C4 Therapeutics Inc (CCCC) market cap?

Today CCCC has the market capitalization of 317.88M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free